Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

+12 or trisomy 12

Written2000-05Lucienne Michaux
Department of Hematology and Center for Human Genetics Cliniques Universitaires Saint Luc Avenue Hippocrate 10 1200 Brussels, Belgium

(Note : for Links provided by Atlas : click)

Identity

ICD-Topo C420,C421,C424 BLOOD, BONE MARROW, & HEMATOPOIETIC SYS
Atlas_Id 2024
Note trisomy 12 is the most common cytogenetic change in chronic lymphocytic leukemia (CLL); however, it has also been observed in other subtypes of B-cell lymphoproliferative disorders, where it is not seldomly a secondary change
 
  trisomy 12 R-banding and FISH - Courtesy Hossein Mossafa.

Clinics and Pathology

Disease B-cell chronic lymphocytic leukemia (B-CLL)
Phenotype / cell stem origin virgin CD5+ recirculating B-cell; the classical CLL phenotype is CD5+, CD23+, CD22-, CD79a-, FMC7-, sIg weak; trisomy 12 is more often observed in CLL with morphologically and immunologically atypical cells, displaying CD5 negativity or FMC7 positivity and strong surface immunoglobulin staining; trisomy 12 is present in proliferating cells and seems to be associated with the absence of mutation of the Ig variable region genes
Epidemiology trisomy 12 is found in one third of cytogenetically abnormal CLLs by conventional karyotype, and in about 12-54% of cases when interphase FISH is used
Prognosis a significant difference comparing the therapy-free interval of patients with +12 and patients with other anomalies was found; this observation was repeatedly confirmed; however an adverse impact of +12 on survival could not be demonstrated until the IWCLL compiled karyotype and survival data from more than 400 patients and showed a median survival of 5.4 years versus 8.6 years versus 14 years in patients with +12 versus another single abnormality versus a normal karyotype, respectively; the preliminary results on a large series of patients analyzed by interphase FISH showed that +12 and 14q+ changes are associated with shorter survival times, compared to patients with 13q abnormalities and normal karyotypes; however prospective data are needed to further assess the prognostic value of this cytogenetic change

Disease B-cell non Hogkin's lymphomas, distinct from CLL, i.e.prolymphocytic leukemia, hairy cell leukemia, splenic lymphoma with villous lymphocytes (SLVL), Waldenström's disease, follicular lymphoma, mantle cell lymphoma, and diffuse large cell lymphoma
Phenotype / cell stem origin lack of specificity for a particular immunophenotype
Prognosis no data are available concerning the prognostic significance of +12, except in one series of mantle cell lymphomas in which it was the only single cytogenetic parameter associated with poor prognosis

Cytogenetics

Cytogenetics Morphological using restriction fragment length polymorphism analysis, the extra chromosome 12 has been shown to derive from duplication of one chromosome 12, with retention of the other homolog rather than from triplication of one homolog; trisomy 12 is thought to be a secondary change since combined immunological and cytogenetic studies showed that it is present in only a part of the neoplastic B-cells; cases with partial duplication 12q were analyzed by FISH, and a "minimal duplicated region" could be defined in segment 12q13-12q15

Bibliography

Trisomy 12 is uncommon in typical chronic lymphocytic leukaemias.
Criel A, Wlodarska I, Meeus P, Stul M, Louwagie A, Van Hoof A, Hidajat M, Mecucci C, Van den Berghe H
British journal of haematology. 1994 ; 87 (3) : 523-528.
PMID 7993792
 
Origin of trisomy 12 in B-cell chronic lymphocytic leukemia.
Crossen PE, Horn HL
Cancer genetics and cytogenetics. 1987 ; 28 (1) : 185-186.
PMID 3475165
 
Cytogenetic profile of lymphoma of follicle mantle lineage: correlation with clinicobiologic features.
Cuneo A, Bigoni R, Rigolin GM, Roberti MG, Bardi A, Piva N, Milani R, Bullrich F, Veronese ML, Croce C, Birg F, Döhner H, Hagemeijer A, Castoldi G
Blood. 1999 ; 93 (4) : 1372-1380.
PMID 9949181
 
Chromosome aberrations in B-cell chronic lymphocytic leukemia: reassessment based on molecular cytogenetic analysis.
Döhner H, Stilgenbauer S, Döhner K, Bentz M, Lichter P
Journal of molecular medicine (Berlin, Germany). 1999 ; 77 (2) : 266-281.
PMID 10023780
 
FISH identifies different types of duplications with 12q13-15 as the commonly involved segment in B-cell lymphoproliferative malignancies characterized by partial trisomy 12.
Dierlamm J, Wlodarska I, Michaux L, Vermeesch JR, Meeus P, Stul M, Criel A, Verhoef G, Thomas J, Delannoy A, Louwagie A, Cassiman JJ, Mecucci C, Hagemeijer A, Van den Berghe H
Genes, chromosomes & cancer. 1997 ; 20 (2) : 155-166.
PMID 9331566
 
Molecular analyses of chromosome 12 in chronic lymphocytic leukemia.
Einhorn S, Burvall K, Juliusson G, Gahrton G, Meeker T
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 1989 ; 3 (12) : 871-874.
PMID 2586180
 
Trisomy 12 in B-cell chronic lymphocytic leukaemia: assessment of lineage restriction by simultaneous analysis of immunophenotype and genotype in interphase cells by fluorescence in situ hybridization.
Garcìa-Marco J, Matutes E, Morilla R, Ellis J, Oscier D, Fantes J, Catovsky D, Price CM
British journal of haematology. 1994 ; 87 (1) : 44-50.
PMID 7947255
 
Correlation of trisomy 12 with expression of the proliferating nuclear antigen K-67 in chronic lymphocytic leukemia.
GarciaMarco J, Matutues E, Price CM, Ellis J, Que TH, Lens D, Catovsky D
Br J Haematol. 1994 ; 86 (numero Suppl 1) : page 24.
 
Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.
Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK
Blood. 1999 ; 94 (6) : 1848-1854.
PMID 10477713
 
Cytogenetic analysis of B cell chronic lymphoid leukemias classified according to morphologic and immunophenotypic (FAB) criteria.
Hernandez JM, Mecucci C, Criel A, Meeus P, Michaux I, Van Hoof A, Verhoef G, Louwagie A, Scheiff JM, Michaux JL
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 1995 ; 9 (12) : 2140-2146.
PMID 8609731
 
Cytogenetic findings and survival in B-cell chronic lymphocytic leukemia.
Juliusson G, Oscier D, Gahrton G
Leukemia Lymphoma. 1991.
 
Trisomy 12 defines a group of CLL with atypical morphology: correlation between cytogenetic, clinical and laboratory features in 544 patients.
Matutes E, Oscier D, Garcia-Marco J, Ellis J, Copplestone A, Gillingham R, Hamblin T, Lens D, Swansbury GJ, Catovsky D
British journal of haematology. 1996 ; 92 (2) : 382-388.
PMID 8603004
 
Catalogue of chromosome aberrations in cancer.
Mitelman F, Johansson B, Mertens F
Wiley..
 
Trisomy 12 in chronic lymphocytic leukemia detected by fluorescence in situ hybridization: analysis by stage, immunophenotype, and morphology.
Que TH, Marco JG, Ellis J, Matutes E, Babapulle VB, Boyle S, Catovsky D
Blood. 1993 ; 82 (2) : 571-575.
PMID 7687164
 
Clinical significance of cytogenetic findings in untreated patients with B-cell chronic lymphocytic leukemia.
Sadamori N, Han T, Minowada J, Sandberg AA
Cancer genetics and cytogenetics. 1984 ; 11 (1) : 45-51.
PMID 6606486
 

Citation

This paper should be referenced as such :
Michaux, L
+12 or trisomy 12
Atlas Genet Cytogenet Oncol Haematol. 2000;4(2):81-82.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Anomalies/tri12ID2024.html


Other genes implicated (Data extracted from papers in the Atlas) [ 1 ]

Genes CD38

External links

arrayMap (UZH-SIB Zurich)
arrayMap[select an item]
 
 
Disease database+12 or trisomy 12
REVIEW articlesautomatic search in PubMed
Last year articlesautomatic search in PubMed
All articlesautomatic search in PubMed


© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Fri Jun 30 11:24:02 CEST 2017


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.